The role of circulating biomarkers in predicting the 30-day mortality of immune checkpoint inhibitors-related myocarditis: a retrospective cohort study

This study aims to find circulating biomarkers that can reflect disease state and prognosis accurately. 48 patients with ICIs-M were enrolled according to the diagnostic criteria for ICIs-related myocarditis. For all enrolled patients, valuable information was extracted retrospectively from the medical system, mainly including demographic information, tumor information and laboratory examination. The follow-up period was defined as 30  days after the first diagnosis of ICIs-M. In this study, the 30-day mortality rate of ICIs-M was 24.4%. After adjusting for potential confounding factors using multivariate analysis tools, we demonstrated the excellent performance of biomarkers in predicting 30-day mortality in patients with ICIs- M, including PLT (hazard ratio (HR), 1.07; 95% confidence interval (95%CI), 1.01–1.14;p = 0.028), ALT (HR, 1.23; 95%CI, 1.06–1.41;p = 0.005), AST(HR, 1.06; 95%CI, 1.01–1.10;p = 0.015), LDH (HR, 1.15; 95%CI, 1.04–1.26;p = 0.004), troponin I(HR, 1.44; 95%CI, 1.09–1.89;p = 0.009), PLR (blood plate/lymphocyte) (HR, 1.04; 95% CI, 1.01–1.07;p = 0.024), LAR (lactate dehydrogenase/albumin) (HR, 1.05; 95%CI, 1.01–1.09;p = 0.012), and AAR (aspartate transaminase/albumin) (HR, 1.18; 95%CI, 1.00–1.39;p = 0.048). The analysis of the receiver operating characteristic showed that biomarkers with area under curve (AUC) greater than or equal to 0.80 were LDH (cutoff value, 724.5; AUC, 0.86; 95%CI, 0.75–0.97),...
Source: Internal and Emergency Medicine - Category: Emergency Medicine Source Type: research